Thursday, 26 March 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 26 March 2026
News

Companies chase listing changes

 Posted 26 March 2026 AM

A dozen companies will hit up the PBAC for changes to listings at the upcoming July meeting, with 15 drugs under consideration.

AstraZeneca has two requests - the first a revised proposal for the listing of Calquence in combination with  bendamustine and rituximab for the first-line treatment of adult patients with Stage III or IV mantle cell lymphoma who are ineligible for stem cell transplantation. A submission made by the company last year won a recommendation at the July 2025 meeting.

To see the whole article, please login

Popular

PBS giant hangs on tight
Most expensive drug out of stock
Where Drs say pharma falls short
Which pharmas are Most Ethical?
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home